|
1
|
Krejci J, Mlejnek D, Sochorova D and Nemec
P: Inflammatory Cardiomyopathy: A current view on the
pathophysiology, diagnosis, and treatment. Biomed Res Int.
2016:40876322016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lauer B, Schannwell M, Kühl U, Strauer BE
and Schultheiss HP: Antimyosin autoantibodies are associated with
deterioration of systolic and diastolic left ventricular function
in patients with chronic myocarditis. J Am Coll Cardiol. 35:11–18.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Binah O: Pharmacologic modulation of the
immune interaction between cytotoxic lymphocytes and ventricular
myocytes. J Cardiovasc Pharmacol. 38:298–316. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kodama M, Matsumoto Y, Fujiwara M, Masani
F, Izumi T and Shibata A: A novel experimental model of giant cell
myocarditis induced in rats by immunization with cardiac myosin
fraction. Clin Immunol Immunopathol. 57:250–262. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spezzacatene A, Sinagra G, Merlo M,
Barbati G, Graw SL, Brun F, Slavov D, Di Lenarda A, Salcedo EE,
Towbin JA, et al: Arrhythmogenic phenotype in dilated
cardiomyopathy: Natural history and predictors of life-threatening
arrhythmias. J Am Heart Assoc. 4:e0021492015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Williams AR and Hare JM: Mesenchymal stem
cells: Biology, pathophysiology, translational findings, and
therapeutic implications for cardiac disease. Circ Res.
109:923–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanganalmath SK and Bolli R: Cell therapy
for heart failure: A comprehensive overview of experimental and
clinical studies, current challenges, and future directions. Circ
Res. 113:810–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelkar AA, Butler J, Schelbert EB, Greene
SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun
W, et al: Mechanisms contributing to the progression of ischemic
and nonischemic dilated cardiomyopathy: Possible modulating effects
of paracrine activities of stem cells. J Am Coll Cardiol.
66:2038–2047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mancini Kizilay O, Shum-Tim D, Stochaj U,
Correa JA and Colmegna I: Age, atherosclerosis and type 2 diabetes
reduce human mesenchymal stromal cell-mediated T-cell suppression.
Stem Cell Res Ther. 6:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hare JM, Fishman JE, Gerstenblith G,
Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker
JA, et al: Comparison of allogeneic vs. autologous bone
marrow-derived mesenchymal stem cells delivered by transendocardial
injection in patients with ischemic cardiomyopathy: The POSEIDON
randomized trial. Jama. 308:2369–2379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karantalis V and Hare JM: Use of
mesenchymal stem cells for therapy of cardiac disease. Circ Res.
116:1413–1430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golpanian S, Wolf A, Hatzistergos KE and
Hare JM: Rebuilding the damaged heart: Mesenchymal stem cells,
cell-based therapy, and engineered heart tissue. Physiol Rev.
96:1127–1168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang HS, Hung SC, Peng ST, Huang CC, Wei
HM, Guo YJ, Fu YS, Lai MC and Chen CC: Mesenchymal stem cells in
the Wharton's jelly of the human umbilical cord. Stem Cells.
22:1330–1337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho PS, Messina DJ, Hirsh EL, Chi N,
Goldman SN, Lo DP, Harris IR, Popma SH, Sachs DH and Huang CA:
Immunogenicity of umbilical cord tissue derived cells. Blood.
111:430–438. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Batsali AK, Kastrinaki MC, Papadaki HA and
Pontikoglou C: Mesenchymal stem cells derived from Wharton's Jelly
of the umbilical cord: Biological properties and emerging clinical
applications. Curr Stem Cell Res Ther. 8:144–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun L, Wang D, Liang J, Zhang H, Feng X,
Wang H, Hua B, Liu B, Ye S, Hu X, et al: Umbilical cord mesenchymal
stem cell transplantation in severe and refractory systemic lupus
erythematosus. Arthritis Rheum. 62:2467–2475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Wang L, Cong X, Liu G, Zhou J, Bai
B, Li Y, Bai W, Li M, Ji H, et al: Human umbilical cord mesenchymal
stem cell therapy for patients with active rheumatoid arthritis:
Safety and efficacy. Stem Cells Dev. 22:3192–3202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Qiu X, Ni P, Qiu X, Lin X, Wu W,
Xie L, Lin L, Min J, Lai X, et al: Immunological characteristics of
human umbilical cord mesenchymal stem cells and the therapeutic
effects of their transplantion on hyperglycemia in diabetic rats.
Int J Mol Med. 33:263–270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Can A, Ulus AT, Cinar O, Celikkan Topal F,
Simsek E, Akyol M, Canpolat U, Erturk M, Kara F and Ilhan O: Human
umbilical cord mesenchymal stromal cell transplantation in
myocardial ischemia (HUC-HEART Trial). A study protocol of a Phase
1/2, controlled and randomized trial in combination with coronary
artery bypass grafting. Stem Cell Rev. 11:752–760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu CB, Huang H, Sun P, Ma SZ, Liu AH, Xue
J, Fu JH, Liang YQ, Liu B, Wu DY, et al: Human umbilical
cord-derived mesenchymal stromal cells improve left ventricular
function, perfusion, and remodeling in a porcine model of chronic
myocardial ischemia. Stem Cells Transl Med. 5:1004–1013. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng M, Wu G, Song Y, Wang L, Tu L, Zhang
L and Zhang C: Celastrol-induced suppression of the MiR-21/ERK
signalling pathway attenuates cardiac fibrosis and dysfunction.
Cell Physiol Biochem. 38:1928–1938. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu H, Li GN, Xie J, Li R, Chen QH, Chen
JZ, Wei ZH, Kang LN and Xu B: Resveratrol ameliorates myocardial
fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in
STZ-induced diabetic mice. BMC Cardiovasc Disord. 16:52016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soetikno V, Sari FR, Sukumaran V,
Lakshmanan AP, Mito S, Harima M, Thandavarayan RA, Suzuki K, Nagata
M, Takagi R and Watanabe K: Curcumin prevents diabetic
cardiomyopathy in streptozotocin-induced diabetic Rats: Possible
involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci.
47:604–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang HW, Lin LM, He HY, You F, Li WZ,
Huang TH, Ma GX and Ma L: Human umbilical cord mesenchymal stem
cells derived from Wharton's jelly differentiate into
insulin-producing cells in vitro. Chinese Med J (Engl).
124:1534–1539. 2011.
|
|
25
|
Zhang C, Zhou G, Cai C, Li J, Chen F, Xie
L, Wang W, Zhang Y, Lai X and Ma L: Human umbilical cord
mesenchymal stem cells alleviate acute myocarditis by modulating
endoplasmic reticulum stress and extracellular signal regulated
1/2-mediated apoptosis. Mol Med Rep. 15:3515–3520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dec GW and Fuster V: Idiopathic dilated
cardiomyopathy. N Engl J Med. 331:1564–1575. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kania G, Blyszczuk P and Eriksson U:
Mechanisms of cardiac fibrosis in inflammatory heart disease.
Trends Cardiovasc Med. 19:247–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eckhouse SR and Spinale FG: Changes in the
myocardial interstitium and contribution to the progression of
heart failure. Heart Fail Clin. 8:7–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Broberg CS and Burchill LJ: Myocardial
factor revisited: The importance of myocardial fibrosis in adults
with congenital heart disease. Int J Cardiol. 189:204–210. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosin NL, Falkenham A, Sopel MJ, Lee TD
and Legare JF: Regulation and role of connective tissue growth
factor in AngII-induced myocardial fibrosis. Am J Pathol.
182:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dobaczewski M, Chen W and Frangogiannis
NG: Transforming growth factor (TGF)-β signaling in cardiac
remodeling. J Mol Cell Cardiol. 51:600–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rosenkranz S, Flesch M, Amann K, Haeuseler
C, Kilter H, Seeland U, Schlüter KD and Böhm M: Alterations of
beta-adrenergic signaling and cardiac hypertrophy in transgenic
mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol.
283:H1253–H1262. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sukumaran V, Watanabe K, Veeraveedu PT,
Thandavarayan RA, Gurusamy N, Ma M, Yamaguchi K, Suzuki K, Kodama M
and Aizawa Y: Telmisartan, an angiotensin-II receptor blocker
ameliorates cardiac remodeling in rats with dilated cardiomyopathy.
Hypertension Res. 33:695–702. 2010. View Article : Google Scholar
|
|
35
|
Yu CM, Tipoe GL, Lai Wing-Hon K and Lau
CP: Effects of combination of angiotensin-converting enzyme
inhibitor and angiotensin receptor antagonist on inflammatory
cellular infiltration and myocardial interstitial fibrosis after
acute myocardial infarction. J Am Coll Cardiol. 38:1207–1215. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moodley Y, Atienza D, Manuelpillai U,
Samuel CS, Tchongue J, Ilancheran S, Boyd R and Trounson A: Human
umbilical cord mesenchymal stem cells reduce fibrosis of
bleomycin-induced lung injury. Am J Pathol. 175:303–313. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Massague J: Integration of Smad and MAPK
pathways: A link and a linker revisited. Genes Dev. 17:2993–2997.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo X and Wang XF: Signaling cross-talk
between TGF-beta/BMP and other pathways. Cell research. 19:71–88.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huby AC, Turdi S, James J, Towbin JA and
Purevjav E: FasL expression in cardiomyocytes activates the ERK1/2
pathway, leading to dilated cardiomyopathy and advanced heart
failure. Clin Sci (Lond). 130:289–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Y, Zhu H, Su Z, Sun C, Yin J, Yuan H,
Sandoghchian S, Jiao Z, Wang S and Xu H: IL-17 contributes to
cardiac fibrosis following experimental autoimmune myocarditis by a
PKCβ/Erk1/2/NF-kappaB-dependent signaling pathway. Int Immunol.
24:605–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sriramula S, Haque M, Majid DS and Francis
J: Involvement of tumor necrosis factor-alpha in angiotensin
II-mediated effects on salt appetite, hypertension, and cardiac
hypertrophy. Hypertension. 51:1345–1351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun M, Chen M, Dawood F, Zurawska U, Li
JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R and Liu
PP: Tumor necrosis factor-alpha mediates cardiac remodeling and
ventricular dysfunction after pressure overload state. Circulation.
115:1398–1407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sivasubramanian N, Coker ML, Kurrelmeyer
KM, MacLellan WR, DeMayo FJ, Spinale FG and Mann DL: Left
ventricular remodeling in transgenic mice with cardiac restricted
overexpression of tumor necrosis factor. Circulation. 104:826–831.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Westermann D, Van Linthout S, Dhayat S,
Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A,
Schultheiss HP and Tschöpe C: Tumor necrosis factor-alpha
antagonism protects from myocardial inflammation and fibrosis in
experimental diabetic cardiomyopathy. Basic Res Cardiol.
102:500–507. 2007. View Article : Google Scholar : PubMed/NCBI
|
